» Articles » PMID: 26116477

Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia

Overview
Journal Ann Thorac Surg
Publisher Elsevier
Date 2015 Jun 28
PMID 26116477
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Background: After pulmonary resection, patients with lung cancer who have idiopathic pulmonary fibrosis (IPF) have been reported to have higher pulmonary morbidity and mortality and poorer outcomes than patients without IPF. However, whether morbidity, mortality, and outcomes differ according to the subtype of idiopathic interstitial pneumonia (IIP) remains unclear.

Methods: The clinical records of 678 patients with non-small cell lung cancer who underwent pulmonary resection were reviewed retrospectively. A total of 103 patients had IIP and were classified into an IPF group and a non-IPF group in accordance with the 2011 statement.

Results: The IPF group comprised 46 patients, and the non-IPF group comprised 57. The 5-year survival rate was significantly higher in the non-IPF group (53.2%) than in the IPF group (22.1%; p = 0.0093). Cause of death was IIP-related respiratory failure in 26.1% (12 of 46) of the patients in the IPF group as compared with 7.0% (4 of 57) of patients in the non-IPF group (p = 0.008). Multivariate Cox analysis indicated that IPF was a significant predictor of long-term survival (hazard ratio 1.910, 95% confidence interval: 1.102 to 3.313; p = 0.021).

Conclusions: Idiopathic pulmonary fibrosis is independently associated with poorer overall survival in patients with lung cancer who undergo pulmonary resection. The decision whether to perform surgery in patients who have lung cancer with IIP should therefore take into account the subtype of IIP and the poorer outcomes associated with IPF.

Citing Articles

Perioperative Anti-Fibrotic Treatment Prevents Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Lung Cancer Surgery.

Bongiolatti S, Salvicchi A, Rosi E, Bargagli E, Mugnaini G, Gonfiotti A Life (Basel). 2024; 14(11).

PMID: 39598304 PMC: 11595336. DOI: 10.3390/life14111506.


Prognostic impact of interstitial lung disease on pulmonary high-grade neuroendocrine carcinoma.

Sakai T, Azuma Y, Kusano M, Kato S, Koezuka S, Iyoda A Sci Rep. 2024; 14(1):21274.

PMID: 39261570 PMC: 11390706. DOI: 10.1038/s41598-024-72267-5.


Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis.

Otoshi R, Ikeda S, Kaneko T, Sagawa S, Yamada C, Kumagai K Cancers (Basel). 2024; 16(9).

PMID: 38730686 PMC: 11083871. DOI: 10.3390/cancers16091734.


Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia.

Fujimoto K, Ikeda S, Tabata E, Kaneko T, Sagawa S, Yamada C Cancers (Basel). 2024; 16(7).

PMID: 38611005 PMC: 11010978. DOI: 10.3390/cancers16071327.


Efficacy and safety of local ablative therapy for patients with NSCLC and coexisting interstitial lung disease.

Shao C, Zhi X, Mao S, Wu L, Yu J, Yang S Thorac Cancer. 2024; 15(10):778-787.

PMID: 38400790 PMC: 10995702. DOI: 10.1111/1759-7714.15258.